Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The firm is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. The company holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.
Follow-Up Questions
Invion Ltd의 CEO는 누구입니까?
Mr. Thian Chew은 2017부터 회사에 합류한 Invion Ltd의 Executive Chairman of the Board입니다.
IVIXF 주식의 가격 성능은 어떻습니까?
IVIXF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Invion Ltd의 주요 사업 주제나 업종은 무엇입니까?
Invion Ltd은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
